VanEck Associates
RARE icon

VanEck Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

VanEck Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,357
Closed -$91K – 1459
2026
Q1 		$91K Sell
4,357
-810
-16% -$18.2K ﹤0.01% 1309
2025
Q4 		$119K Buy
5,167
+2,517
+95% +$82.8K ﹤0.01% 1315
2025
Q3 		$80K Buy
2,650
+549
+26% +$16.5K ﹤0.01% 1332
2025
Q2 		$76K Buy
2,101
+308
+17% +$11.1K ﹤0.01% 1313
2025
Q1 		$65K Buy
1,793
+33
+2% +$1.37K ﹤0.01% 1297
2024
Q4 		$74K Buy
1,760
+273
+18% +$13.5K ﹤0.01% 1283
2024
Q3 		$81K Sell
1,487
-457
-24% -$23.3K ﹤0.01% 1261
2024
Q2 		$80K Buy
1,944
+36
+2% +$1.54K ﹤0.01% 1264
2024
Q1 		$89K Buy
1,908
+330
+21% +$15.6K ﹤0.01% 1241
2023
Q4 		$75K Buy
1,578
+400
+34% +$15.5K ﹤0.01% 1261
2023
Q3 		$42K Buy
1,178
+29
+3% +$1.15K ﹤0.01% 1296
2023
Q2 		$53K Buy
+1,149
New +$53.3K ﹤0.01% 1300

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

VanEck Associates's RARE Position: Q2 2026 in Review

VanEck Associates sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 4,357 shares — an estimated $91K sold.

VanEck Associates first reported a position in RARE in Q2 2023 and held it in 12 quarters. The position peaked at $119K in Q4 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • VanEck Associates reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • VanEck Associates sold 4,357 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $91K.
  • VanEck Associates first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and held it in 12 quarters.
  • VanEck Associates's Ultragenyx Pharmaceutical position peaked at $119K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.